Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group

• Published in: International journal of radiation oncology, biology, physics Vol. 50; no. 4; pp. 883 - 887
• Main Authors: Ngan, Samuel Y.K, Burmeister, Bryan H, Fisher, Richard, Rischin, Danny, Schache, David J, Kneebone, Andrew, MacKay, John R, Joseph, David, Bell, Andrew, Goldstein, David
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 15.07.2001; Elsevier
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - radiotherapy; Adenocarcinoma - surgery; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic - adverse effects; Antimetabolites, Antineoplastic - therapeutic use; Biological and medical sciences; Combined Modality Therapy; Confidence Intervals; Diarrhea - etiology; Diseases of the digestive system; Female; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Male; Medical sciences; Middle Aged; Neoplasm Staging; Postoperative Complications; Preoperative radiotherapy; Radiotherapy Dosage; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Rectal cancer; Rectal Neoplasms - drug therapy; Rectal Neoplasms - radiotherapy; Rectal Neoplasms - surgery; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Preoperative radiotherapy; Rectal cancer; Antineoplastic agent; Human; Focal lesion; Rectal disease; Toxicity; Treatment efficiency; Fluoropyrimidine derivatives; Stage classification; Malignant tumor; Radiotherapy; Chemotherapy; Phase II trial; Rectum; Digestive diseases; Intestinal disease; Pyrimidine derivatives; Advanced stage; Preoperative; Therapeutic protocol; Fluorouracil

Purpose: To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum. Methods and Materials: Eligible patients had newly diagnosed localized adenocarcinoma of the rectum within 12 cm of the anal...